Spruce Biosciences vs SciSparc
SPRB and SPRC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | SPRB | SPRC |
|---|---|---|
| Size and price | ||
| Market cap | $133M | – |
| Share price | $46.20 | $0.398 |
| Change, 1 year | −60.0% | −98.4% |
| Change, 5 years | −79.0% | −100.0% |
| Beta (5Y) | – | 0.33 |
| Employees | 8 | 3 |
| StockData Score | ||
| Total score | 3 | 3 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 0 |
| Health score | 2 | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 2.0× | – |
| Growth | ||
| Revenue growth (TTM) | – | −34.5% |
| EPS growth (TTM) | – | −51.9% |
| EPS growth, 5Y average | – | 36.4% |
| Profitability | ||
| Gross margin | – | 73.7% |
| Operating margin | – | −978% |
| Net margin | – | −1423% |
| Return on equity | −187% (better) | −770% |
| Financial health | ||
| Debt / equity | 0.12 | 0.09 (better) |
| Interest coverage | −21.3× | −1.0× (better) |
| Current ratio | 4.83 (better) | 0.87 |
| Altman Z-score | −3.45 | – |
| Piotroski F-score | 3 | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 69.7% | – |
| Held by insiders | 71.7% | 15.6% |
| Insider net buying, 12 months | – | −$4.6K |
| Short interest, % of float | 65.3% | 22.5% |
Go deeper
- SPRB stock overview
- SPRB income statement
- SPRB valuation and score
- SPRC stock overview
- SPRC income statement
- SPRC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.